All In Biotech

Drug Trial Radar · NCT06221072

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,360 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,360

Planned (sponsor's estimate)

Start

Apr 5, 2024

Primary completion

May 31, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.

Conditions

  • Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Interventions

  • JMT103Drug

    120 mg by subcutaneous injection every 4 weeks

  • zoledronic acidDrug

    4 mg by intravenous drip (100mL:4mg) every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the First on-study Skeletal-Related Event (SRE)Time frame: Up to approximately 48 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.